Marked hemiatrophy in carriers of Duchenne muscular dystrophy. by Rajakulendran, S. et al.
OBSERVATION
Marked Hemiatrophy in Carriers
of Duchenne Muscular Dystrophy
Sanjeev Rajakulendran, MRCP; Thierry Kuntzer, MD; Murielle Dunand, MD; Shu C. Yau, PhD;
Emma J. Ashton, PhD; Helen Storey, PhD; Joanna McCauley, BSc; Stephen Abbs, PhD;
Francine Thonney, PhD; France Leturcq, PhD; Johannes A. Lobrinus, MD; Tarek Yousry, FRCR;
Simon Farmer, FRCP; Janice L. Holton, PhD; Michael G. Hanna, FRCP
Objective: To describe the clinical and molecular ge-
netic findings in 2 carriers of Duchenne muscular dys-
trophy (DMD) who exhibited marked hemiatrophy.
Duchenne muscular dystrophy is an X-linked disorder
in which affected male patients harbor mutations in the
dystrophin gene. Female patients with heterozygous mu-
tations may be manifesting carriers.
Design: Case study.
Setting: Neurology clinic.
Patients: Two manifesting carriers of DMD.
Interventions: Clinical and radiologic examinations
along with histologic and molecular investigations.
Results: Both patients had marked right-sided hemiat-
rophy on examination with radiologic evidence of
muscle atrophy and fatty replacement on the affected
side. In each case, histologic analysis revealed a reduc-
tion in dystrophin staining on the right side. Genetic
analysis of the dystrophin gene revealed a tandem ex-
onic duplication in patient 1 and a multiexonic deletion
in patient 2 with no further point mutations identified
on the other chromosome.
Conclusions: Marked hemiatrophy can occur in DMD
manifesting carriers. This is likely to result from a
combination of skewed X-inactivation and somatic
mosaicism.
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M ANIFESTINGCARRIERSOFDuchenne musculardystrophy (DMD) areheterozygous sympto-matic female patients
who generally present with a milder phe-
notype than affected male patients. The
phenotypic spectrum of the manifesting
carrier is broad, encompassing cramps,
myalgia, muscle weakness, dilated cardi-
omyopathy, and, rarely, progressive proxi-
mal weakness.1 This report describes 2
manifesting carriers of DMD who pre-
sented with striking right-sided asym-
metrical hemiatrophy in the presence of
normal left-sided musculature. We pre-
sent clinical, genetic, radiologic, and his-
tologic data and suggest that a combina-
tion of skewed X-inactivation and somatic
mosaicism are the likely underlying
mechanisms accounting for this unusual
presentation.
Consent was obtained from both pa-
tients. Genomic DNA was extracted from
leukocytes via a Chemagic Magnetic Sepa-
ration Module I using the 3-mL Chemagic
DNA blood kit special (chemagen Bio-
polymer-Technologie AG, Baesweiler, Ger-
many) or via a Nucleon BACC3 kit (GE
Healthcare, Piscataway, New Jersey). Mul-
tiplex ligation-dependent probe amplifi-
cation (MLPA) analysis using probe sets
P034 and P035 (MRC-Holland, Amster-
dam, the Netherlands) was performed ac-
cording to the manufacturer’s instruc-
tions. Muscle RNA was extracted from
frozen muscle biopsy specimens using the
RNeasy Fibrous Tissue Mini kit (Qiagen,
Düsseldorf, Germany). Muscle DNA was
extracted from frozen muscle biopsy speci-
mens using organic extraction. To am-
plify the exon 10-11 duplication in pa-
tient 1, reverse transcriptase–polymerase
chain reaction (RT-PCR) amplification was
performed, as previously described.2
Open muscle biopsy specimens were
frozen in 2-methyl-butane or isopentane,
cooled by liquid nitrogen, and stored at
−80°C. Ten-micrometer-thick sections
were stained with hematoxylin-eosin, pe-
riodic acid–Schiff reagent, oil red O, Congo
red, and a modified Gomori stain. En-
zyme histochemical analysis with NADH
(nicotinamide adenine dinucleotide)-
tetrazolium-reductase, and adenosine tri-
phosphatase at pH 4.2 and 4.6 was per-
formed according to standard techniques.
For immunohistochemical analysis, the
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following antiserum solutions were used: ubiquitin (rab-
bit polyclonal antibody, code No. Z 0458, 1:200; Dako Corp,
Carpinteria, Calif,); spectrin (mouse monoclonal anti-
body [mAb], clone SPEC1, 1:200 Novocastra Laborato-
ries Ltd, Newcastle upon Tyne, England); dystrophin I, II,
and III (mouse mAb, clones DYS1, DYS2, and DYS3, 1:20;
Novocastra); and utrophin I and II ( mouse mAb, clones
DRP1/12B6 and DRP2/20C5, 1:20; Novocastra).
REPORT OF CASES
CASE 1
Patient 1 presented at age 50 years with an 18-year his-
tory of progressive wasting and weakness in her right arm
and right leg. There was no family history of muscular
dystrophy. The musculature in the left arm and leg was
unaffected as were her facial muscles. She denied any car-
diac symptoms.
On examination we found marked wasting of her right
arm and leg with weakness proximally (Medical Research
Council [MRC] grade 3/5) more than distally (Figure1A
and B). The biceps, supinator, knee, and ankle reflexes on
the right were absent but present on the left side. The left
arm and leg were entirely normal on examination. The cre-
atinine kinase level was elevated (1448 U/L; reference range,
200 U/L). (To convert creatinine kinase to microkatals
per liter, multiply by 0.0167.) An echocardiogram showed
left ventricular dilatation. A magnetic resonance imaging
(MRI) scan of her legs revealed clear right-sided muscle at-
rophy with fatty replacement compared with the left, which
was only slightly infiltrated in the posterior compartment
(Figure 1D).
Histologic examination of the affected right quadri-
ceps muscle demonstrated reduced staining for dystro-
phin in scattered fibers (Figure 2A-D). DNA sequenc-
ing of the 79 coding exons of the DMD gene (OMIM
300377) did not identify any point mutations, but MLPA
analysis revealed a heterozygous duplication of exons
10 and 11, which is predicted to cause a frame shift
(Figure3A). X-inactivation studies from genomic DNA,
according to the previously published method,3 re-
vealed a ratio of 0.88, a result suggestive of nonrandom
X-inactivation. However, clearly the inactivation pat-
tern, at least in the lymphocytes, was not completely
skewed.
To investigate the effect of this duplication on the pa-
tient’s dystrophin in muscle messenger RNA (mRNA),
RT-PCR analysis was performed using primers located
in the coding sequence of exons 9 and 13 of the DMD
gene and with primers designed to amplify across the du-
plication breakpoint at the RNA level.4 In both cases, no
mutant RT-PCR products were detected. Sequence analy-
sis of the patient’s dystrophin complementary DNA tran-
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Figure 1. Wasting and atrophy in the subject patients. A and B, Wasting of the right arm and right leg in patient 1. C, Wasting and weakness of the right arm in
patient 2. D and E, Magnetic resonance images of patients 1 and 2, respectively, demonstrating atrophy of the thigh muscles on the right with fatty replacement.
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script showed that she was heterozygous for the exon 53
coding sequencing polymorphism r.7728u→c, which had
been previously detected in her genomic DNA.
CASE 2
Patient 2 presented at age 35 years with progressive asym-
metrical wasting and weakness of her right arm and leg with
exertion-dependent myalgia and cramps but with no car-
diac symptoms. Examination revealed wasting and weak-
ness of her right arm (Figure 1C) and leg. Her left side was
unaffected. Deep tendon reflexes were absent on the right
side and normal on the left. The creatinine kinase level was
elevated at 958 U/L. An MRI scan of her thighs revealed
fatty degeneration of the muscles on the right, while the
left side showed slight but clear fatty infiltration of muscles
from the posterior compartment (Figure 1E). Her echo-
cardiogram showed no abnormalities.
Immunostaining of affected deltoid muscle from the
right demonstrated a reduced expression of dystrophin
compared with the clinically unaffected left side
(Figures 2E-H); this was further confirmed by Western
blot analysis, which showed a profound reduction in dys-
trophin expression in the right deltoid. Patient 2 was the
mother of a boy diagnosed with DMD who was found to
have a deletion of exons 3 through 13 of the DMD gene
(Figure 3B). Although, this mutation is predicted to main-
tain the translation reading frame, it is likely that it has
a severe disruptive affect on the function of the F-actin
domain of the affected son’s truncated dystrophin pro-
tein, explaining his DMD phenotype. Genetic analysis of
the DMD gene of patient 2 showed that she was a carrier
of this mutation (Figure 3B). X-inactivation studies on
lymphocyte DNA revealed no difference in methylation
between the 2 X chromosomes. Cytogenetic analysis re-
vealed a normal karyotype, thus excluding Turner syn-
drome as a possible cause.
COMMENT
The identification of a pathogenic duplication of DMD
exons 10 and 11 in patient 1 and a deletion of exons 3
through 13 in patient 2 are consistent with both pa-
tients being manifesting carriers of DMD. Immunohis-
tochemical studies on affected muscle further sup-
A B C D
Patient 1
E F G H
Patient 2
Figure 2. Histologic studies of the subject patients. A and B, Right quadriceps biopsy specimens of frozen muscle from patient 1 show increased variation in fiber
size, a mild increase in endomysial connective tissue, and several fibers containing internal nuclei. C, Reduced staining for dystrophin (asterisks) in a small
proportion of fibers from patient 1. D, The same fibers demonstrated increased expression of utrophin (asterisks). E and F, Histologic specimens of deltoid muscle
from patient 2 demonstrate a dystrophic pattern on the right (E) compared with the left (F). G and H, Patient 2 dystrophin immunostains of the right deltoid
muscle (G) show a mosaic expression of dystrophin-positive fibers and dystrophin-negative fibers, whereas the left-sided muscle sections (H) reveal only
sporadic dystrophin-negative fibers.
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Figure 3. Multiplex ligation-dependent probe amplification traces showing
peak heights. The red peak is a control peak of known copy number with
which the patient’s DNA (blue peak) is compared. A, Patient 1 (P1) shows a
50% increase in peak height for exons 10 and 11 compared with the control
(C), consistent with a tandem duplication. B, Patient 2 (P2) has a 50%
reduction in peak height for exons 11, 12, and 13 compared with the control,
indicating that she has only 1 copy of each of these exons. Her affected son
(S) had no copies of exons 11 through 13.
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ported their carrier status: the biopsy specimens from both
patients clearly demonstrated a reduction in dystrophin
staining with compensatory upregulation of utrophin.4
Patient 1 was also found to be heterozygous for a syn-
onymous polymorphism in the coding sequence of exon
53 (c.7728t→c and r.7728u→c) at both the genomic DNA
and RNA levels, indicating that she expressed dystro-
phin mRNA from both of her X chromosomes. A sensi-
tive RT-PCR assay was used to amplify the mutant mRNA
transcript from affected muscle, but we were nonethe-
less unable to detect the presence of the duplication. This
suggests either that the mutant mRNA was not present
at a sufficient level for detection, or that the mutation is
more complex than a straightforward tandem duplica-
tion, in which case our RT-PCR assay would not be able
to detect it.
The striking clinical feature in both patients was
marked asymmetrical wasting. Although mild asym-
metrical weakness is a common occurrence in DMD car-
riers, marked hemiatrophy is very unusual. In addition,
patient 1 had a dilated cardiomyopathy, which is de-
scribed in approximately 8% of manifesting carriers.1 The
MRI studies correlated with the marked asymmetrical phe-
notype but also indicated subclinical involvement of left-
sided muscles.
The manifestation of X-linked recessive disorders in
female patients is generally considered to arise from
skewed X-inactivation, a process that is normally ran-
dom and ensures dosage equalization of X-linked genes
between XX female and XY male subjects.5 Since no sec-
ond DMD mutation was detected in the other chromo-
some in either patient, their phenotype is predicted to
arise from nonrandom or skewed X-inactivation result-
ing in overexpression of the mutant X chromosome. Al-
though X-inactivation ratios in lymphocyte DNA were
normal in case 2 and suggestive of skewing in case 1, the
pattern is likely to be tissue specific; hence, the result does
not exclude higher levels of skewed X-inactivation in the
affected muscle tissue.6 It is possible that the higher 0.88
ratio seen in patient 1 may be the result of age-related
skewing of X-inactivation.7
Skewed X-inactivation alone would not account for the
very marked asymmetrical presentation. It is possible that
the marked asymmetry reflects a disproportionately high
expression of the X-chromosome carrying the mutantDMD
gene on the more affected side, with preferential inacti-
vation of the X chromosome harboring wild-type DMD.
This may have arisen from an event early in embryogen-
esis when the X-chromosome–carrying wild-typeDMDun-
derwent preferential inactivation in the progenitor cells
destined to become the muscles of the affected side. This
event may have been either stochastic or genetic, involv-
ing for example the XIST gene,8 a key player in the X-
inactivation pathway. One can speculate that mosaicism
of theXIST gene could account for the marked asymmetri-
cal skewed inactivation.
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